Synthesis of novel heterobimetallic copper(I) hydrazone Schiff base complexes: A comparative study on the effect of heterocyclic hydrazides towards interaction with DNA/protein, free radical scavenging and cytotoxicity

Department of Chemistry, Bharathiar University, Coimbatore 641 046, India.
Metallomics (Impact Factor: 3.59). 04/2012; 4(5):498-511. DOI: 10.1039/c2mt00004k
Source: PubMed

ABSTRACT Two new copper(I) hydrazone complexes have been synthesised from bivalent copper precursor [CuCl(2)(PPh(3))(2)] and ferrocene containing bidentate hydrazone ligands HL(1) (1) or HL(2) (2). Based on the elemental analyses and spectroscopic data, the complexes are best formulated as [CuL(1)(PPh(3))(2)] (3) and [CuL(2)(PPh(3))(2)] (4) of the monovalent copper ion. Solid state structures of ligand 2 and its corresponding complex 4 were also determined. The DNA/albumin interactions of all the synthesised compounds were investigated using absorption, emission and synchronous fluorescence studies. Further, antioxidant properties of all the compounds have also been checked against ABTS, O(2)(-) and OH radicals. Additionally, the in vitro cytotoxic activity of compounds 1-4 was assessed using tumour (HeLa, A431) and non-tumour (NIH 3T3) cell lines.

Download full-text


Available from: Dharmaraj Nallasamy, Sep 26, 2015
231 Reads
    • "Multinuclear platinum(II ) complexes [7], platinum(IV) prodrugs [8e11], platinum photoactivable drugs [12] [13], and platinum(II) drug delivery strategies (polymers, nanoparticles and oligonucleotides) [14] [15] have emerged. Other metallodrugs based on ruthenium [16], gold [17] [18], titanium [19], copper [20], iron [21] [22], have also attracted great interest. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Twelve cyclometallated palladium(II) complexes containing primary aromatic amines [benzylamine (a), (R)-1-(1-naphthyl)ethylamine (b) and 2-phenylaniline (c)] as anionic bidentate (C,N)(-) ligands have been evaluated against a panel of human adenocarcinoma cell lines (A549 lung, MDA-MB231 and MCF7 breast, and the cisplatin resistant HCT116 colon). The results revealed a remarkable antiproliferative activity of the triphenylphosphane mononuclear compounds 3-4 (series a, b, c) and the best inhibition was provided for 3c and 4c with the 2-phenylaniline ligand and a six membered chelate ring. Interestingly, 3c and 4c were 14 and 19 times more potent than cisplatin for the inhibition of the cisplatin resistant HCT116 human adenocarcinoma cell line, respectively. Cyclopalladated complexes 3c and 4c exercise their antiproliferative activity over A549 cells mainly through the induction of apoptosis (38 and 31-fold increase in early apoptotic cells, respectively).
    European Journal of Medicinal Chemistry 07/2014; 84C:530-536. DOI:10.1016/j.ejmech.2014.07.046 · 3.45 Impact Factor
  • Source
    • "The Schiff base ligands are considered as " privileged ligands " because they are easily prepared by the condensation between aldehydes and imines, and their use of analytical and biological processes on different models has solved many serious problems [2] [3]. Over the past decade, the synthesis of the privileged classes of heterocyclic molecules has become one of the main areas of interest in synthetic chemistry [1] [2]. These important structures have gained much attention, owing to their potential role as ligands, which are capable of binding multiple biological targets [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The 3-(2-aminophenyl) quinazolin-2-methyl-4(3H)-one and 2,4-dihydroxyacetophenone undergo condensation to afford (E)3-2-(1-(2,4-dihydroxyphenyl)ethyldeneamino) phenyl)-2- methylquinazoline-4(3H)-one Schiff base (DHPEAPMQ). The newly synthesized Schiff base (DHPEAPMQ) and its metal complexes were evaluated for their antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from the Gulbarga region in India. The Cu(II), Ni(II), and Zn(II) complexes of Schiff base (DHPEAPMQ) showed good antimicrobial activity. So, this could be a new drug of choice.
    Bioinorganic Chemistry and Applications 01/2014; · 1.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The synthesis and characterization of a new water-soluble iminophosphorane ligand TPA=N-C(O)-2BrC(6)H(4) (C,N-IM; TPA = 1,3,5-triaza-7-phosphaadamantane) 1 is reported. Oxidative addition of 1 to Pd(2)(dba)(3) affords the orthopalladated dimer [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) as a mixture of cis and trans isomers (1:1 molar ratio) where the iminophosphorane moeity behaves as a C,N-pincer ligand. By addition of different neutral or monoanionic ligands to 2, the bridging bromide can be cleaved and a variety of hydrophilic or water-soluble mononuclear organometallic palladium(II) complexes of the type [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L-L)] (L-L = acac (3); S(2)CNMe(2) (4); 4,7-Diphenyl-1,10-phenanthrolinedisulfonic acid disodium salt C(12)H(6)N(2)(C(6)H(4)SO(3)Na)(2) (5)); [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L)Br] (L = P(mC(6)H(4)SO(3)Na)(3) (6); P(3-Pyridyl)(3) (7)) and, [Pd(C(6)H(4)(C(O)N=TPA)-2}(TPA)(2)Br] (8) are obtained as single isomers. All new complexes were tested as potential anticancer agents and their cytotoxicity properties were evaluated in vitro against human Jurkat-T acute lymphoblastic leukemia cells, normal T-lymphocytes (PBMC) and DU-145 human prostate cancer cells. Compounds [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) and [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(acac)] 3 (which has been crystallographically characterized) display the higher cytotoxicity against the above mentioned cancer cell lines while being less toxic to normal T-lymphocytes (peripheral blood mononuclear cells: PBMC). In addition, 3 is very toxic to cisplatin resistant Jurkat shBak indicating a cell death pathway that may be different to that of cisplatin. The interaction of 2 and 3 with plasmid (pBR322) DNA is much weaker than that of cisplatin pointing to an alternative biomolecular target for these cytotoxic compounds. All the compounds show an interaction with human serum albumin (HSA) faster than that of cisplatin.
    Organometallics 08/2012; 31(16):5772-5781. DOI:10.1021/om3006239 · 4.13 Impact Factor
Show more